Core Viewpoint - Ningbo Meinuohua Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the raw material drug Atorvastatin Calcium, which will enhance the company's product line and business scope [1][3]. Group 1: Registration Information - The registration number for Atorvastatin Calcium is Y20240000440, and it is produced by Xuancheng Meinuohua Pharmaceutical Co., Ltd. in Anhui [1]. - The product is available in various packaging specifications: 5kg, 10kg, 15kg, 20kg, and 25kg [1]. - The approval indicates that the product meets the requirements for drug registration under the Drug Administration Law of the People's Republic of China [1]. Group 2: Indications and Pharmacological Action - Atorvastatin Calcium is indicated for the treatment of hypercholesterolemia and mixed hyperlipidemia, as well as for the prevention and treatment of coronary heart disease [2]. - The drug functions as a statin, primarily acting in the liver to reduce cholesterol synthesis, increase low-density lipoprotein receptor synthesis, lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately decrease serum triglyceride levels, and increase high-density lipoprotein levels [2]. Group 3: Impact on the Company - Xuancheng Meinuohua submitted the review application for Atorvastatin Calcium on May 16, 2024, and it passed the review on December 17, 2025, with a cumulative R&D investment of 14.9496 million yuan [3]. - The approval of Atorvastatin Calcium demonstrates compliance with national drug review technical standards, allowing the product to be sold in the domestic market, which will enrich the subsidiary's product line and help expand the company's business scope [3].

Company Announcements - Guo Xin Technology's former actual controller Chen Chongjun was sentenced to six years in prison and fined 4 million yuan for manipulating the securities market [2] - Zhongwei Company is planning to acquire the controlling stake in Hangzhou Zhonggui, leading to a stock suspension [3] - Xusheng Group's controlling shareholder is planning a change of control, resulting in a stock suspension [4] - Yidong Electronics' major shareholders reduced their holdings by 2.3463 million shares between December 10 and December 17 [5] - Nandu Power's controlling shareholder has terminated plans for a change of control, leading to stock resumption [6] - Xibu Mining's subsidiary obtained a mining license for a site with 2.86 tons of gold metal [8] Financial Adjustments - Shandong Highway plans to provision for a long-term equity investment impairment of approximately 690 million yuan related to Dongxing Securities [8] - WuXi AppTec's third and fourth largest shareholders reduced their holdings by a total of 29.508 million shares between November 26 and December 17 [9] Investments and Partnerships - Weixinno plans to sign an investment cooperation agreement to advance the Hefei 8.6 generation AMOLED production line project with a capital of 9.443 billion yuan [10] - Jiangnan New Materials is investing 300 million yuan to build a high-end copper-based core material R&D and industrialization project [15] Shareholding Changes - Sichuan Road and Bridge received a stake increase from Zhongyou Insurance, raising its holding to 5% [11] - Lidasin's fifth largest shareholder reduced their holdings by 1.56% between December 10 and December 17 [12] - Ruicheng Environmental Protection's shareholder plans to reduce their holdings by up to 3% [17] Dividends and Profit Distribution - Haitian Flavoring plans to maintain a cash dividend ratio of no less than 80% for the next three years (2025-2027) [13] - CICC announced a cash dividend distribution of 434 million yuan for the first half of 2025, with a record date of December 26 [14] Financing and Listings - Baipusais plans to issue H-shares and list on the Hong Kong Stock Exchange [21]

Group 1 - Shandong Zhanggu received administrative regulatory measures from the Shandong Securities Regulatory Commission due to issues related to related party transactions, information disclosure violations, improper use of raised funds, and non-compliance in corporate governance [1] - Nanjing Pharmaceutical plans to invest 120 million yuan to establish a medical device investment company, holding a 59.9% stake, which will focus on investing in Ningbo Jiangfeng Biological Information Technology Co., Ltd. [2] - ST Mingjia's stock will be suspended for one day on December 19 due to the implementation of its restructuring plan [3] Group 2 - Baotai's application for the marketing authorization of BAT5906 has been accepted by the National Medical Products Administration [4] - Nanhua Futures has set the final price for its H-share public offering at 12 HKD per share, with trading expected to begin on December 22 [5] - Visionox plans to invest 3.918 billion yuan in the second phase of capital contribution to Hefei Guoxian, increasing its shareholding to 37.73% [6] Group 3 - Dafu Technology intends to transfer 49% of its stake in Dasheng Graphite at a base price of 206 million yuan [7] - Aorite has passed the GMP compliance inspection for its production lines [8] - CICC announced a cash dividend distribution of 434 million yuan for the first half of 2025, with a dividend of 0.09 yuan per share [9][10] Group 4 - Sichuan Road and Bridge received a stake increase from Zhongyou Insurance, raising its holding to 5% [11] - Jinhua Co. plans to apply for a comprehensive credit line of 185 million yuan from Guangfa Bank [12] - Huicheng Environmental Protection's private placement has been approved by the China Securities Regulatory Commission [13] Group 5 - Junwei Electronics has established a joint venture with Placo New Materials in Hong Kong [14] - Huaye Fragrance appointed Gao Ming as the deputy general manager [15] - Yongmaotai received a government subsidy of 17.2242 million yuan, accounting for 45.92% of its net profit for the last audited fiscal year [16] Group 6 - Haitian Flavoring plans a special dividend of 3 yuan per 10 shares, totaling 1.754 billion yuan [17] - Haizheng Pharmaceutical's subsidiary received a new veterinary drug registration certificate [18] - Hailianxun's share swap merger with Hangzhou Qilun has been approved by the CSRC [19] Group 7 - ST Shuangcheng's injection of bortezomib ANDA has been approved by the US FDA [20] - Tibet Pharmaceutical plans to repurchase shares worth between 170 million and 200 million yuan [21] - Jiayuan Technology has set a preliminary transfer price of 39.93 yuan per share for its inquiry transfer [22] Group 8 - Jiemai Technology has invested in Beijing Critical Field Technology Co., Ltd. [23] - Zotye Auto plans to reach a settlement with SAIC Transmission Company regarding a contract dispute [24] - Xianju Pharmaceutical's application for the registration of estradiol tablets has been accepted [25] Group 9 - Xinya Electronics has established a subsidiary focused on urban rail transit technology [26] - Southern Precision has received a total credit line of 179 million yuan from ICBC and CCB [27] - Ningbo Construction's subsidiary won a 747 million yuan engineering project [28] Group 10 - Whirlpool plans to sign a supplementary agreement regarding component procurement with Whirlpool Corporation [29] - Haixiang New Materials intends to sell part of its under-construction factory for 41.3774 million yuan [30] - Menohua's subsidiary's atorvastatin calcium raw material drug application has been approved [31] Group 11 - Beilu Pharmaceutical plans to use up to 500 million yuan of idle funds for cash management [32] - Jiangnan New Materials plans to invest 300 million yuan in a high-end copper-based core material project [33] - Jinqilin's CRH380D train brake pads have passed small-scale trials [34] Group 12 - China Chemical signed contracts worth 352.569 billion yuan from January to November 2025 [35] - Guanghuan New Network plans to apply for an additional credit line of 300 million yuan [36] - Zhengye Technology signed a 120 million yuan equipment procurement contract [38] Group 13 - Xinno's subcutaneous injection of secukinumab has achieved primary endpoint success in its Phase III clinical trial [39] - Qinglong Pipe Industry signed a procurement contract worth 55.2671 million yuan [40]

Core Viewpoint - The company Menohua has received approval from the National Medical Products Administration for its atorvastatin calcium raw material drug, which will enhance its product line and expand its business scope [1] Group 1: Regulatory Approval - Menohua's subsidiary Xuancheng Menohua received the approval notice for atorvastatin calcium raw material drug with registration number Y20240000440 [1] - The application for the drug was submitted to the CDE on May 16, 2024, and it passed the review on December 17, 2025, with a registration status marked as "A" [1] Group 2: Financial Investment - The total R&D investment for the atorvastatin calcium raw material drug amounted to 14.9496 million yuan (approximately 2.1 million USD) [1] Group 3: Business Impact - The approval of atorvastatin calcium will enrich the product line of the subsidiary and help expand the company's business areas [1] - It will further enhance the integrated production capabilities of the company in the raw material drug formulation sector [1]

Core Viewpoint - Meinuo Pharma (603538.SH) has received approval from the National Medical Products Administration for its atorvastatin calcium raw material drug, which will enhance its product line and expand its business scope [1] Group 1: Regulatory Approval - The company’s subsidiary, Xuancheng Meinuo, received the approval notice for atorvastatin calcium raw material drug with registration number Y20240000440 [1] - The application for the drug was submitted to the CDE on May 16, 2024, and it passed the review on December 17, 2025, with a registration status marked as "A" [1] Group 2: Financial Investment - The total R&D investment for the atorvastatin calcium raw material drug amounted to 14.9496 million yuan (approximately 2.1 million USD) [1] Group 3: Business Expansion - The approval of atorvastatin calcium raw material drug will enrich the subsidiary's product line and help expand the company's business areas [1] - This development is expected to enhance the company's integrated production advantages in the raw material drug formulation sector [1]

Core Viewpoint - The company Menova (603538.SH) announced that its subsidiary Xuancheng Menova Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the marketing application of atorvastatin calcium raw material [1] Group 1 - Xuancheng Menova's atorvastatin calcium raw material has passed the CDE technical review, confirming that it meets national drug review technical standards [1] - The approval allows the raw material to be sold in the domestic market, which will enrich the subsidiary's product line [1] - This development is expected to help expand the company's business scope and enhance its integrated production advantages in the raw material and formulation sectors [1]

Core Viewpoint - The announcement indicates that Meinuohua's subsidiary has received approval for the production of atorvastatin calcium, a drug used for treating high cholesterol and preventing coronary heart disease [1] Group 1: Company Developments - Meinuohua's subsidiary, Xuancheng Meinuohua Pharmaceutical Co., Ltd., has received the approval notice from the National Medical Products Administration for atorvastatin calcium raw material [1] - Atorvastatin calcium is indicated for the treatment of hypercholesterolemia and mixed dyslipidemia, as well as for the prevention and treatment of coronary heart disease [1]

Core Viewpoint - The company Minohua (603538.SH) has received approval from the National Medical Products Administration for the marketing application of atorvastatin calcium raw material, which will enhance its product line and business scope [1] Group 1: Regulatory Approval - Minohua's subsidiary, Xuancheng Minohua Pharmaceutical Co., Ltd., has obtained the approval notice for atorvastatin calcium raw material from the National Medical Products Administration [1] - The atorvastatin calcium raw material has passed the CDE technical review, confirming its compliance with national drug review technical standards [1] Group 2: Business Expansion - The approval will enrich the product line of the subsidiary, aiding in the expansion of the company's business areas [1] - It is expected to further extend the company's integrated production range of raw materials and formulations, enhancing its integrated production advantages [1]

浙江海森药业股份有限公司 首次公开发行股票并在主板上市发行公告 保荐人（主承销商）：中信证券股份有限公司 特别提示 浙江海森药业股份有限公司（以下简称"海森药业"、"发行人"或"公司"） 根据《证券发行与承销管理办法》（证监会令【第 208 号】）（以下简称"《管 理办法》"）、《首次公开发行股票注册管理办法》（证监会令【第 205 号】） （以下简称"《注册办法》"）、《深圳证券交易所首次公开发行证券发行与承 销业务实施细则》（深证上〔2023〕100 号）（以下简称"《业务实施细则》"）、 《深圳市场首次公开发行股票网上发行实施细则》（深证上〔2018〕279 号）（以 下简称"《网上发行实施细则》"）及《深圳市场首次公开发行股票网下发行实 施细则（2023 年修订）》（深证上〔2023〕110 号）（以下简称"《网下发行实 施细则》"）、《首次公开发行证券承销业务规则》（中证协发〔2023〕18 号） （以下简称"《承销业务规则》"）、《首次公开发行证券网下投资者管理规则》 （中证协发〔2023〕19 号）（以下简称"《网下投资者管理规则》"）等有关股 票发行上市规则和最新操作指引等相关法律法规、监管规 ...